Oxymetazoline Hydrochloride

ApprovedSmall molecule

Oxymetazoline Hydrochloride is one of 79 small molecule programs targeting Non-Allergic Rhinitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Allergic RhinitisActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Allergic RhinitisActive, not recruiting

Non-Allergic RhinitisPreclinical

Active, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

Allergic RhinitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 2

Rayos

RRoxane Laboratories

Phase 3

1 3

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 4

Oxymetazoline Hydrochloride

UUniversity of South Florida

Approved

1 5

REGN1908-1909

Regeneron

Phase 3

1 6

Asmanex

Novartis

Preclinical

12 7

Veramyst

GSK

Preclinical

10 8

Singulair

AstraZeneca

Preclinical

5 9

Xolair

Roche

Preclinical

1 10

Bilaxten

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

POI1 trial

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Completed·AActavis Inc.·Phase 3·NCT03954444·1,105 enrolled

Allergic Rhinitis1 trial

Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis

Completed·EEgalet Ltd·Phase 1·NCT01365650·24 enrolled

Obstructive Sleep Apnea1 trial

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

Recruiting·UUniversity of South Florida·Phase 4·NCT02630121·52 enrolled

Ketorolac1 trial

Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine

Completed·EEgalet Ltd·Phase 1·NCT01363089·21 enrolled

Non-Allergic Rhinitis1 trial

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

Terminated·UUniversity of South Florida·N/A·NCT00584662·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Oxymetazoline Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxymetazoline Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxymetazoline Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of South Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of South Florida

Oxymetazoline Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

POI1 trial

Allergic Rhinitis1 trial

Obstructive Sleep Apnea1 trial

Ketorolac1 trial

Non-Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News